Volatile markers of breast cancer in the breath

Breast Journal

Volumn 9, Issue 3, 2003, Pages 184-191

  Phillips, Michael ^a,b   Cataneo, Renee N ^a   Ditkoff, Beth Ann ^c   Fisher, Peter ^c   Greenberg, Joel ^a   Gunawardena, Ratnasiri ^d   Kwon, C Stephan ^d   Rahbari Oskoui, Farid ^a   Wong, Cynthia ^b,d  

^a MENSSANA RESEARCH INC   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d ST VINCENT S HOSPITAL   (United States)

Author keywords

Breast cancer; Breath; Oxidative stress; Screening; Volatile organic compounds

Indexed keywords

ALKANE; ALKANE DERIVATIVE; BIOCHEMICAL MARKER; METHYL GROUP; VOLATILE ORGANIC COMPOUND;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREATH ANALYSIS; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FEMALE; GAS CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIPID PEROXIDATION; LUNG ALVEOLUS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASS SPECTROMETRY; OXIDATIVE STRESS; PILOT STUDY; PREDICTION; TREATMENT INDICATION; TREATMENT OUTCOME; VALIDATION PROCESS;

AGED; ALKANES; BREAST NEOPLASMS; BREATH TESTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; METHYLATION; MIDDLE AGED; NEW YORK; PILOT PROJECTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VOLATILIZATION;

EID: 0037736535     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2003.09309.x     Document Type: Article

References (26)

1. Henderson C. Breast cancer. In: Wilson J, Braunwald E, Petersdorf RG, eds. Harrison's Principles of Internal Medicine, 12th ed. New York: McGraw-Hill, 1991.
2. Ambrosone CB. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000;2:903-17.
3. Li D, Zhang W, Sahin AA, Hittelman WN. DNA adducts in normal tissue adjacent to breast cancer: a review. Cancer Detect Prev 1999;23:454-62.
4. Knight JA. Free radicals: their history and current status in aging and disease. Ann Clin Lab Sci 1998;28:331-46.
5. Kneepkens CM, Lepage G, Roy CC. The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic Biol Med 1994;17:127-60.
6. Phillips M, Cataneo RN, Greenberg J, Gunawardena R, Naidu A, Rahbari-Oskoui F. Effect of age on the breath methylated alkane contour, a display of apparent new markers of oxidative stress. J Lab Clin Med 2000;136:243-49.
7. Hietanen E, Bartsch H, Bereziat JC, et al. Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. Eur J Clin Nutr 1994;48:575-86.
8. Humad S, Zarling E, Clapper M, Skosey JL. Breath pentane excretion as a marker of disease activity in rheumatoid arthritis. Free Radic Res 1988;5:101-6.
9. Weitz ZW, Birnbaum AJ, Sobotka PA, Zarling EJ, Skosey JL. High breath pentane concentrations during acute myocardial infarction. Lancet 1991;337:933-35.
10. Phillips M, Sabas M, Greenberg J. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. J Clin Pathol 1993;46:861-64.
11. Olopade CO, Zakkar M, Swedler WI, Rubinstein I. Exhaled pentane levels in acute asthma. Chest 1997;111:862-65.
12. Zarling EJ, Mobarhan S, Bowen P, Kamath S. Pulmonary pentane excretion increases with age in healthy subjects. Mech Ageing Dev 1993;67:141-47.
13. Phillips M. Method for the collection and assay of volatile organic compounds in breath. Anal Biochem 1997;247:272-78.
14. Rosen PP. Rosen's Breast Pathology. Philadelphia: Lippincott-Raven, 1997.
15. Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo RN. Variation in volatile organic compounds in the breath of normal humans. J Chromatogr B Biomed Appl 1999;729:75-88.
16. SPSS for Windows standard version. Chicago, IL: SPSS Inc., 1998.
17. Jennrich R. Stepwise discriminant analysis. In: Enslein K, Ralston A, Wilf H, eds. Statistical Methods for Digital Computers. New York: Wiley, 1977.
18. Efron B. The Jackknife, the Bootstrap, and Other Resampling Plans. Philadelphia: Society for Industrial and Applied Mathematics, 1982.
19. SEER data, 1984-1988. In: National Cancer Institute Statistics Review 1975-1988. NIH publication no. 91-2789. Bethesda, MD: National Institutes of Health, 1991 [cited in Kopans DB. Breast Imaging, 2nd ed. Philadelphia: Lippincott-Raven, 1998:31, Table 3-2].
20. SEER data, 1984-1988. In: National Cancer Institute Statistics Review 1975-1988. NIH publication no. 91-2789. Bethesda, MD: National Institutes of Health, 1991 [cited in Kopans DB. Breast Imaging, 2nd ed. Philadelphia: Lippincott-Raven, 1998:31, Table 3-2].
21. Baines CJ, McFarlane DV, Miller AB. Sensitivity and specificity of first screen mammography in 15 NBSS centres. Can Assoc Radiol J 1988;39:273-76.
22. Watanabe M. Polymorphic CYP genes and disease predisposition - what have the studies shown so far? Toxicol Lett 1998;102-103:167-71.
23. Murray GI. The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 2000;192:419-26.
24. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996;24:899-905.
25. Kneepkens CM, Ferreira C, Lepage G, Roy CC. The hydrocarbon breath test in the study of lipid peroxidation: principles and practice. Clin Invest Med 1992;15:163-86.
26. Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999;353:1930-33.